These findings not only offer a reliable, supportive preclinical data for ARDS predictions but also suggest that Toll-like receptor 9 (TLR9), an inhibitor of a major mtDNA receptor [47,48], represents a potential target for the treatment of sepsis-associated ARDS. Here, TLR9 is linked to Sepsis.